<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017415</url>
  </required_header>
  <id_info>
    <org_study_id>BC-09774</org_study_id>
    <nct_id>NCT05017415</nct_id>
  </id_info>
  <brief_title>Applicability of Uroflowmetry in Children With Cerebral Palsy</brief_title>
  <official_title>What is the Difference in the Applicability of the Uroflowmetry Between Children With Cerebral Palsy (CP) With Lower Urinary Tract Symptoms (LUTS) and Without Lower Urinary Tract Symptoms (LUTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Until now, the use of invasive urodynamics with use of catheters is still the gold standard&#xD;
      for lower urinary tract evaluation in subjects with CP. This suggests a psychological and&#xD;
      physical impact of invasive urodynamics in subjects with CP and further demonstrates the need&#xD;
      to avoid standard use of invasive urodynamics in children and adults with CP.&#xD;
&#xD;
      The current study will evaluate usefulness of uroflowmetry, correlation between uroflowmetry&#xD;
      parameters and different lower urinary tract symptoms will be investigated. Secondly, results&#xD;
      of uroflowmetry indicating possible vulnerability of the upper urinary tract will be defined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cross-sectional case-control study comparing children with CP and LUTS and children with CP&#xD;
      without LUTS will be conducted with the primary objective to investigate correlation between&#xD;
      uroflowmetry parameters and different LUTS.&#xD;
&#xD;
      Children will be evaluated with uroflowmetry and subsequent post void residual measurement&#xD;
      and the validated vancouver symptom score for dysfunctional elimination syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 14, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Children will be randomised in two groups, with evaluation with a standard toilet seat or a toilet seat with decreased hip angle.</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of pathological uroflow patterns - Qualitative assessment</measure>
    <time_frame>During cross-sectional testing</time_frame>
    <description>Interpretation by pediatric urologist following ICCS classification Measured during uroflowmetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of pathological uroflow patterns - Quantitative assessment</measure>
    <time_frame>During cross-sectional testing</time_frame>
    <description>Interpretation using Flow index methodology Measured during uroflowmetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal flow</measure>
    <time_frame>During cross-sectional testing</time_frame>
    <description>Measured during uroflowmetry Qmax (mililitres/seconds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influencing factors for uroflow measurement</measure>
    <time_frame>During cross-sectional testing</time_frame>
    <description>Functional impairment of the child&#xD;
hip angle&#xD;
Vancouver symptom score for dysfunctional elimination syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voided volume</measure>
    <time_frame>During cross-sectional testing</time_frame>
    <description>Measured during uroflowmetry mililitres Percentage of expected bladder capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual urine</measure>
    <time_frame>During cross-sectional testing</time_frame>
    <description>Measured with CUBEscan BioCon 700 mililiters Percentage of voided volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cerebral Palsy</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Standard toilet chair (hip angle 90°)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toilet chair with decreased hip angle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uroflow measurement</intervention_name>
    <description>Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie</description>
    <arm_group_label>Standard toilet chair (hip angle 90°)</arm_group_label>
    <arm_group_label>Toilet chair with decreased hip angle</arm_group_label>
    <other_name>uroflowmetry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bladder ultrasound</intervention_name>
    <description>Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700</description>
    <arm_group_label>Standard toilet chair (hip angle 90°)</arm_group_label>
    <arm_group_label>Toilet chair with decreased hip angle</arm_group_label>
    <other_name>US</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cerebral palsy&#xD;
&#xD;
          -  Dutch or French speaking child and parent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of urological surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bieke Samijn, dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ghent University Hospital/Ghent University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bieke Samijn, dr.</last_name>
    <phone>+32 9 332 19 38</phone>
    <email>bieke.samijn@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <state>Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bieke Samijn</last_name>
      <phone>09 332 19 38</phone>
      <email>Bieke.Samijn@ugent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral palsy</keyword>
  <keyword>lower urinary tract symptoms</keyword>
  <keyword>incontinence</keyword>
  <keyword>uroflow measurement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

